OptimizeRx(OPRX) - 2025 Q3 - Quarterly Results

million and $22 million OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance - Q3 revenue of $26.1 million, increased 22% year-over-year - Q3 gross profit increased 30% year-over-year to $17.5 million Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million - Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range bet ...